Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors

Published:2022-11 Issue: Volume:179 Page:103806
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Rebuzzi Sara Elena,Prelaj Arsela,Friedlaender Alex,Cortellini Alessio,Addeo Alfredo,Genova Carlo,Naqash Abdul Rafeh,Auclin Edouard,Mezquita Laura,Banna Giuseppe Luigi

Funder

Ministero della Salute

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference93 articles.

1. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis;Addeo;Front. Oncol.,2019

2. Tumor mutation burden-from hopes to doubts;Addeo;JAMA Oncol.,2019

3. TMB or not TMB as a biomarker: that is the question;Addeo;Crit. Rev. Oncol. /Hematol.,2021

4. Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis;Akinboro;J. Clin. Oncol.,2021

5. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience;Arkenau;Br. J. Cancer,2008

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors;Biomedicines;2024-08-12

2. Peripheral Blood Biomarkers Predicting the Efficacy of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Retrospective Study;2024-07-02

3. Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations;Cancers;2024-03-22

4. The Gastric Cancer Immune Prognostic Score (GCIPS) Shows Potential in Predicting an Unfavorable Prognosis for Gastric Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment;Biomedicines;2024-02-22

5. Advanced lung cancer inflammation index predicts overall survival of hepatocellular carcinoma after hepatectomy;Frontiers in Oncology;2024-02-08